RBC Capital analyst Craig Wong-Pan maintained a Hold rating on CSL (CMXHF – Research Report) on January 29 and set a price target of A$286.00.

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark. In the UK, health technology ...

After hours: February 3 at 5:59:47 PM EST Loading Chart for CSL ...

Research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines.

Blackhawk developer Kenneth E. Behring, known for his worldwide philanthropy and booming business and development career that included helping transform the Tri-Valley and serving as the one-time ...

Please view our affiliate disclosure. Creating a strong brand identity is one of the most important aspects of a business. A well-designed logo is often the first impression a company makes on ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.